Literature DB >> 17435619

Case files from Stanford University Medical Center: ten years of HAART: a long wait for full HIV suppression.

Nancy Shulman1, Robert W Shafer.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17435619      PMCID： PMC1925029     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  9 in total

1.  HIV type 1 fitness evolution in antiretroviral-experienced patients with sustained CD4+ T cell counts but persistent virologic failure.

Authors:  Julia G Prado; Neil T Parkin; Bonaventura Clotet; Lidia Ruiz; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2005-07-22       Impact factor: 9.079

2.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance.

Authors:  Soo-Yon Rhee; Jonathan Taylor; Gauhar Wadhera; Asa Ben-Hur; Douglas L Brutlag; Robert W Shafer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-25       Impact factor: 11.205

3.  Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.

Authors:  Jing Lu; Steven G Deeks; Rebecca Hoh; George Beatty; Benjamin A Kuritzkes; Jeffrey N Martin; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2006-09       Impact factor: 3.731

4.  Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.

Authors:  Cecilia Cabrera; Silvia Marfil; Elisabet García; Javier Martinez-Picado; Anna Bonjoch; Margarita Bofill; Santiago Moreno; Esteban Ribera; Pere Domingo; Bonaventura Clotet; Lidia Ruiz
Journal:  AIDS       Date:  2006-10-24       Impact factor: 4.177

5.  Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Authors:  John D Baxter; Jonathan M Schapiro; Charles A B Boucher; Veronika M Kohlbrenner; David B Hall; Joseph R Scherer; Douglas L Mayers
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

6.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

Authors:  S G Deeks; T Wrin; T Liegler; R Hoh; M Hayden; J D Barbour; N S Hellmann; C J Petropoulos; J M McCune; M K Hellerstein; R M Grant
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

7.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

Authors:  A K Iversen; R W Shafer; K Wehrly; M A Winters; J I Mullins; B Chesebro; T C Merigan
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

9.  Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

Authors:  T Shirasaka; M F Kavlick; T Ueno; W Y Gao; E Kojima; M L Alcaide; S Chokekijchai; B M Roy; E Arnold; R Yarchoan
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-14       Impact factor: 11.205
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.